Pharming Group NV (PHARM) — Long-term Investment Intensity
Pharming Group NV (PHARM) has a Long-term Investment Intensity of 1.4% as of September 2025. Long-term investments of €6.67 Million represent 1.4% of total assets of €473.79 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check PHARM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Pharming Group NV Long-term Investment Intensity (2019–2024)
This chart shows how Pharming Group NV's Long-term Investment Intensity has evolved across 6 annual periods from 2019 to 2024. As of September 2025, the intensity stands at 1.4%, reflecting long-term investments of €6.67 Million against total assets of €473.79 Million EUR. Explore how well can Pharming Group NV service its debt to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Pharming Group NV (2019–2024)
The table below presents the year-by-year Long-term Investment Intensity for Pharming Group NV from 2019 to 2024, covering 6 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see how much is Pharming Group NV worth.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 1.1% | €4.23 Million | €386.88 Million | ▼ -1.3 pp |
| 2023 | 2.4% | €10.40 Million | €426.34 Million | ▲ +0.2 pp |
| 2022 | 2.3% | €9.73 Million | €425.80 Million | ▲ +0.1 pp |
| 2021 | 2.2% | €8.79 Million | €396.90 Million | ▲ +0.8 pp |
| 2020 | 1.4% | €5.80 Million | €419.12 Million | ▼ -0.7 pp |
| 2019 | 2.1% | €5.31 Million | €255.63 Million | — |